Please try another search
For the six months ended 30 June 2016, Vitae Pharmaceuticals Inc revenues decreased 82% to $55K. Net loss increased 5% to $20.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and Administrative Expense increase of 12% to $4.3M (expense), Stock-based Compensation in SGA increase of 67% to $827K (expense).
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Revenue | 0 | 0.05 | 0.09 | 0.18 |
Gross Profit | ||||
Operating Income | -10.54 | -10.08 | -11.79 | -13.16 |
Net Income | -10.41 | -10.01 | -11.45 | -13.07 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Assets | 88.33 | 61.85 | 72.07 | |
Total Liabilities | 5.84 | 7.38 | 7.7 | |
Total Equity | 82.49 | 54.47 | 64.37 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Period Length: | 0 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -10.54 | -38.04 | -27.24 | |
Cash From Investing Activities | 19.49 | -12.06 | -16.78 | |
Cash From Financing Activities | 37.63 | 32.38 | 31.46 | |
Net Change in Cash | 46.58 | -17.72 | -12.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review